Globally, cervical cancer is the most appearing cancer in women. Cervical cancer is most frequently diagnosed in women between the age of 35 and 44 with the average age of diagnosis being 50. In 2019, an estimated 283.15 Million women were diagnosed with cervical cancer worldwide, and about 311,000 women died from the disease in 2018. Cervical cancer is the fourth most common cancer prevailing in women and the seventh in terms of overall cancer incidences. There are three types of screening for identifying cervical cancer they are Pap Smear Tests, Human Papillomavirus Virus (HPV) Tests and Visual Inspection with Acetic Acid (VIA) Tests. These screenings are key factor anticipated to boost the number of screening tests over the forecast period. Effective primary (HPV vaccination) approach (testing and treating precancerous lesions) will prevent most cervical cancer cases. According to Renub Research report, Cervical Cancer Screening Market is expected to be USD 16.5 Billion by 2026.